Questions and responses 42nd Parliament, 1st session December 3, 2015, to September 11, 2019

With regard to studies conducted by, or on behalf of, Health Canada, since January 1, 2016: (a) what studies have been done on the side effects of Mifegymiso, including (i) date, (ii) methodology, (iii) who conducted the study, (iv) location, (v) finding; and (b) what data has been collected on the side effects of Mifegymiso, broken down by (i) each of the known side effects of Mifegymiso, (ii) Health Canada's estimate on the number of Canadians affected by each of the known side effects of Mifegymiso?

With regard to the $911 million in grants allocated to research projects and personnel support in Supplementary Estimates (C) 2016-17 to the Canadian Institute of Health Research: what funds have been granted thus far, broken down by (i) recipient, (ii) amount, (iii) project description?

With regard to Health Canada's decisions taken with respect to Mifegymiso: (a) is Health Canada capturing data on the safety and efficacy of Mifegymiso on Canadian patients; (b) if the answer to (a) is affirmative, (i) how is the data being obtained, (ii) what data is being obtained, (iii) will the data be made public; (c) will Health Canada conduct a Canadian post-market study independent of the drug manufacturer Linepharma on the safety of Mifegymiso; (d) if the answer to (c) is affirmative, (i) on what date will the study commence, (ii) on what date will the study end, (iii) what methodology will be used, (iv) where will the study be conducted; (e) will Health Canada ensure that the drug manufacturer Linepharma conducts a Phase IV Observational Study on the safety of Mifegymiso on Canadian women; and (f) if the answer (e) is affirmative, (i) on what date will the study commence, (ii) on what date will the study end, (iii) what methodology will be used, (iv) where will the study be conducted?